Journal of Biological Chemistry · 2010 · 100 citations · 50 references
Life SciencesMolecular BiologyOncologyCell SignalingGene ExpressionSignal TransductionCancer Cell SignalingGrowth Factor SignalingMammary TumorsNuclear ReceptorsOncogenic Signaling PathwaysSignal Transduction In CancerCancer Cell Proliferation InhibitionCell Growth RegulationEgfr InhibitionEpidermal Growth Factor Receptor SignalingErbb Receptor SignalingFatty Acid BindingNf-kappa B-dependent TranscriptionPeroxisome Proliferator-activated Receptor Signaling
Epidermal growth factors and their receptors (EGFRs) promote breast cancer cell proliferation and can drive tumorigenesis. However, the molecular mechanisms that mediate these effects are incompletely understood. We previously showed that mammary tumor development in the mouse model of breast cancer MMTV-neu, a model characterized by amplification of the EGFR ErbB2 in mammary tissue, correlates with a marked up-regulation of fatty acid-binding protein 5 (FABP5). FABP5 functions to deliver ligands to and enhance the transcriptional activity of the nuclear receptor peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta), a receptor whose target genes include genes involved in cell growth and survival. We show here that in MCF-7 mammary carcinoma cells, EGFR signaling directly up-regulates the expression of FABP5. The data demonstrate that treatment of these cells with the EGFR ligand heregulin-beta1 signals through the ERK and the phophatidylinositol-3-kinase cascades, resulting in activation of the transcription factor NF-kappaB. In turn, NF-kappaB induces the expression of FABP5 through two cognate response elements in the promoter of this gene. The observations further demonstrate that FABP5 and PPARbeta/delta are critical mediators of the ability of EGFR to enhance cell proliferation, indicating that this transcriptional pathway plays a key role in EGFR-induced tumorigenesis. Additional observations indicate that the expression of FABP5 is down-regulated by the Krüppel-like factor KLF2, suggesting a tumor suppressor activity for this factor.
50
Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations
Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer
Dennis J. Slamon, William Godolphin, Lovell A. Jones et al. · Science · 1989 · 6.9K citations
William J. Muller, Eric Sinn, Paul K. Pattengale et al. · Cell · 1988 · 1.2K citations
Medicine, Cancer Biology, Oncology +14